Jordanian field hospital begins operations in Gaza, treats over 1,000 patients
Its field hospital director said that medical and nursing teams had treated over 1,000 patients in specialized clinics that operate round the clock to address various medical needs.
'We take pride in our presence in Gaza and our unwavering commitment to serve our Palestinian brothers and sisters with distinction and professionalism,' the hospital's force commander told the Jordan News Agency.
The facility includes clinics for dermatology, orthopedics, pediatrics, maxillofacial surgery, internal medicine, and gynecology. It also provides neonatal intensive care and operates a mobile prosthetic limb support unit, in addition to offering facilities for general surgery, vascular surgery, neurosurgery, plastic surgery, and burns treatment.
The hospital team this week supplied 11 trucks of humanitarian aid, relief items, and medical supplies to support Gaza's health infrastructure, as part of the Jordanian Armed Forces' broader efforts to help Palestinians.
Jordan was among the first countries to conduct airlift missions in the early days of the conflict and has delivered relief to Gaza since late 2023.
It has partnered with several humanitarian organizations, including the World Health Organization, the World Food Programme, and World Central Kitchen, to implement food and medical projects aimed at assisting Palestinians in Gaza.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Arab News
an hour ago
- Arab News
GHF aid distribution sites in Gaza becoming ‘laboratories of cruelty,' says medical charity
LONDON: Doctors Without Borders has accused a controversial aid initiative in Gaza of enabling the systematic targeting and killing of civilians, it was reported on Thursday. In a scathing new report, the medical charity — also known by its French acronym MSF— said aid distribution centers run by the US and Israeli-backed Gaza Humanitarian Foundation had become sites of 'orchestrated killing.' Raquel Ayora, one of the charity's general directors, said: 'In MSF's nearly 54 years of operations, rarely have we seen such levels of systematic violence against unarmed civilians. 'The GHF distribution sites masquerading as 'aid' have morphed into a laboratory of cruelty. This must stop now.' The group is calling for GHF's operations to be scrapped immediately and replaced with a UN-led system. It has urged governments and donors to 'suspend all financial and political support for the GHF.' In a report by Sky News, the channel contacted both the GHF and the Israel Defense Forces for comment. In an interview on Wednesday, IDF spokesperson Nadav Shoshani dismissed the allegations, claiming: 'I think that is completely false,' and described some reports of shootings as 'fake news.' Between June 7 and July 24, MSF says it treated 1,380 people wounded near GHF aid sites at two of its clinics. Among the injured were 71 children, 25 of them under the age of 15. The charity said 28 people were dead on arrival. Among the cases were an 8-year-old girl shot in the chest, and a 12-year-old boy hit in the abdomen. The charity described several injuries as precise and deliberate. 'The distinct patterns and anatomical precision of these injuries strongly suggests the intentional targeting of people within and around the distribution sites, rather than accidental or indiscriminate fire,' the report stated. Gunshot wounds recorded at MSF's Al-Mawasi Clinic showed 11 percent struck victims in the head or neck, while 19 percent were to the torso. In Khan Younis, injuries to the lower limbs were more common. One patient, Mohammed Riad Tabasi, said: 'We're being slaughtered. I've been injured maybe 10 times. I saw it with my own eyes, about 20 corpses around me; all of them shot in the head (and) in the stomach.' The report also documented 196 injuries caused by stampedes or chaos during aid distribution. One woman died of likely asphyxiation in a crush. Others, MSF said, were beaten or robbed after receiving food. The GHF took over much of Gaza's aid provision in May after Israel ended an 11-week blockade. But the operation has drawn mounting international criticism. A previous Sky News investigation linked GHF-led aid drops to spikes in fatalities, and UN officials have condemned the system as 'death traps.' UN experts this week called the program 'an utterly disturbing example of how humanitarian relief can be exploited for covert military and geopolitical agendas in serious breach of international law.' They reiterated calls for Israel to restore access for UN agencies and humanitarian nongovernmental organizations. MSF echoed the demand and directly urged the US to end its support. 'Despite the condemnations and calls for dismantling it, the global inaction to stop GHF is baffling,' said Aitor Zabalgogeazkoa, MSF's emergency coordinator. The IDF maintains that humanitarian access is not being obstructed. 'There is no limit of aid getting into Gaza,' Shoshani said. 'Every day, hundreds of trucks go into Gaza.' Israeli officials argue the GHF model prevents supplies being stolen by Hamas and ensures they reach civilians directly. Steve Witkoff, the US' special envoy to the Middle East, last week toured one of the sites. 'We're putting up money to get the people fed,' US President Donald Trump declared at the same time.
Arab News
4 hours ago
- Arab News
Gaza Humanitarian Foundation to ‘scale up' number of sites from 4 to 16
LONDON: The US and Israeli-backed Gaza Humanitarian Foundation will 'scale up' its sites in Gaza from four to 16, US Ambassador to Israel Mike Huckabee has said. In an interview with Fox News, Huckabee said: 'The immediate plan is to scale up the number of sites up to 16 and begin to operate them as much as 24 hours a day.' The GHF was conceived by Israelis, is operated by American contractors on the ground, and receives diplomatic and financial support from the US, The New York Times reported. It currently operates four aid distribution sites, mostly in southern Gaza. Huckabee and Steve Witkoff, the US' special envoy to the Middle East, visited a GHF site in the enclave last week. Huckabee's comments are viewed as a response to mounting criticism of Israel's war and humanitarian strategy for Gaza. Aid groups have warned that the enclave is in the grip of a rapidly worsening hunger crisis, with Palestinians confronting famine levels of food insecurity. The World Food Programme, a UN body, has said that the humanitarian crisis in Gaza has reached 'new and astonishing levels of desperation, with one-third of the population not eating for multiple days in a row.' Observers widely viewed the launch of the GHF as an Israeli attempt to supersede Gaza's existing humanitarian network, which was largely run by the UN. The foundation has been severely criticized by the UN and has faced a boycott, after UN officials said its methods violated humanitarian law. Hundreds of Palestinians seeking food have been shot dead near GHF sites since the foundation began operations in May, health workers in the enclave have said. Israeli forces are stationed close to the sites, and the country's military said its troops had fired 'warning shots' toward crowds of desperate Palestinians. Huckabee said: 'The president has been telling us he wants food into the hands of hungry people, but he wants it in a way that it doesn't get into the hands of Hamas. That's exactly what we did when we stood up GHF.' He added that the foundation coordinated with the Israeli military but was not under its control, and that its results were 'pretty phenomenal.'
Al Arabiya
7 hours ago
- Al Arabiya
Lilly weight-loss pill helps patients shed 12.4 pct of body weight in trial
Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4 percent of their body weight after 72 weeks in a late-stage study—slightly less than results from a previous trial of Novo Nordisk's injectable obesity drug Wegovy. Unlike injectable treatments, which are peptides designed to mimic the appetite-regulating GLP-1 hormone, orforglipron is a small-molecule pill that is easier to manufacture and package, said Kenneth Custer, president of Lilly's cardiometabolic health division. Lilly, whose injectable GLP-1 drug Zepbound competes directly with Wegovy, views the once-daily pill as a promising alternative to injections for early intervention and long-term disease management. 'We have pretty big aspirations for how many patients orforglipron could help,' Custer said, adding that Lilly expects to file for regulatory approval before the end of the year. In a study of more than 3,000 overweight or obese adults with weight-related health issues—but not diabetes—those who received the highest 36-milligram dose of orforglipron lost 12.4 percent of their body weight, compared with 0.9 percent in the placebo group. Patients on the 6 mg dose lost 7.8 percent. The most common side effects were mild to moderate gastrointestinal issues. Among those on the highest dose, 33.7 percent experienced nausea and 24 percent experienced vomiting, compared with 10.4 percent and 3.5 percent, respectively, in the placebo group. Just over 10 percent of high-dose patients dropped out of the trial due to side effects. No liver safety issues were reported. At least three analysts said the market had expected orforglipron to match Wegovy's 14.9 percent weight loss over 68 weeks, as shown in a 2021 trial, with some hoping Lilly's pill might surpass Novo's. Zepbound and Wegovy currently dominate the booming weight-loss market, which analysts expect could reach $150 billion by the early 2030s. The US Food and Drug Administration is reviewing a high-dose oral version of Wegovy for potential approval later this year. Novo said it helped patients lose 15 percent of their body weight in a late-stage trial. Custer said orforglipron can be taken without restrictions on food or water. Lilly also said the drug lowered markers of heart disease risk—such as cholesterol, triglycerides, and blood pressure—across all doses. Wegovy has been approved to reduce the risk of major heart problems, and Lilly recently released data showing similar heart-protective qualities for its diabetes drug Mounjaro, which contains the same active ingredient as Zepbound. Such approvals would likely boost insurance coverage of weight-loss medications. Earlier this year, Lilly announced that a Phase 3 study showed type 2 diabetes patients lost nearly eight percent of their body weight after 40 weeks on orforglipron. The company has already begun manufacturing the drug in order to stockpile supply ahead of a commercial launch, hoping to avoid the shortages that plagued early demand for injectable treatments. Full trial results will be presented next month at a major European diabetes conference, the Indianapolis-based drugmaker said.
